Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-03-22
2005-03-22
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391100, C530S387300, C424S133100
Reexamination Certificate
active
06870033
ABSTRACT:
Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 5147537 (1992-09-01), Sada et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5169627 (1992-12-01), Cunningham-Rundles
patent: 5527528 (1996-06-01), Allen et al.
patent: 5532150 (1996-07-01), Snow et al.
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5620689 (1997-04-01), Allen et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5661020 (1997-08-01), Snow et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5677426 (1997-10-01), Fong et al.
patent: 5679532 (1997-10-01), Repine
patent: 5686070 (1997-11-01), Doerschuk et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5698196 (1997-12-01), Matsushima et al.
patent: 5702946 (1997-12-01), Doerschuk et al.
patent: 5707622 (1998-01-01), Fong et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5874080 (1999-02-01), Hebert et al.
patent: 770628 (1997-05-01), None
patent: WO 9204372 (1992-03-01), None
patent: WO 9412219 (1994-06-01), None
patent: WO 9421235 (1994-09-01), None
patent: WO 9511987 (1995-05-01), None
patent: WO 9515769 (1995-06-01), None
patent: WO 9523813 (1995-09-01), None
patent: WO 9523865 (1995-09-01), None
patent: WO 9532003 (1995-11-01), None
patent: WO 9602576 (1996-02-01), None
patent: WO 9609325 (1996-03-01), None
patent: WO 9622785 (1996-08-01), None
patent: WO 9634015 (1996-10-01), None
patent: WO 9640733 (1996-12-01), None
patent: WO 9701354 (1997-01-01), None
patent: WO 9710847 (1997-03-01), None
patent: WO 9740215 (1997-10-01), None
patent: WO 9825971 (1998-06-01), None
patent: WO 9837200 (1998-08-01), None
patent: WO 9937779 (1999-07-01), None
Wilchek et al., Methods in Enzymology 104:3-8, 10-11, 17-18, and 21-22, 1984.*
Rudikoff et al, PNAS 79:1979, 1982.*
Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts”Enzymes as Drugs,Holcenberg, JS; Roberts. J eds. New York: Wiley, Chapter 13, pps. 367-383 (1981).
Adagen LabelPhysicians' Desk Reference(Product Information), 48 edition, Montvale, NJ:Medical Economics Data Production Company pps. 917-918 (1994).
Allen et al., “A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells”Biochimica et Biophysica Acta1237(2):99-108 (Jul. 26, 1995).
Anderson and Tomasi, “Polymer modification of antibody to eliminate immune complex and Fc binding”Journal of Immunological Methods109(1):37-42 (Apr. 22, 1988).
Beauchamp et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulin”Analytical Biochemistry131(1):25-33 (1983).
Bernard et al., “The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination”American Journal of Respiratory&Critical Care Medicine149 (3 Pt 1):818-824 (Mar. 1994).
Brooks and Stocks, Use of polyacrylamide-derivatized antibody in dextran-poly(ethylene glycol) systemsMethods in Enzymology228:390-395 (1994).
Brumeanu et al., “Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements”Journal of Immunology154 (7):3088-3095, (Apr. 1, 1995).
Carter et al.. “Preparation and uses of Fab' fragments fromEscherichia coli” Antibody Engineering: a Practical Approach,Hoogenboom, H., McCafferty, J., Chiswell. D. eds., Oxford, UK:IRL Press, Chapter 13 pps. 291-308 (1996).
Chamow et al., “Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation”Bioconjugate Chemistry5(2):133-140 (Mar.-Apr. 1994).
Chapman et al., “Therapeutic antibody fragments with prolonged in vivo half-lives”Nature Biotechnology17(8):780-783 (Aug. 1999).
Clark et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”Journal of Biological Chemistry271(36):21969-21977 (Sep. 6, 1996).
Cunningham-Rundles et al., “Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation”Journal of Immunological Methods152(2):177-190 (Aug. 10, 1992).
Davis et al., “Soluble. Nonantigenic Polyethylene Gylcol-Bound Enzymes”Biomedical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use,Goldberg, E and Nakajima, A eds., New York:Academic Press pps. 441-452 (1980).
Delgado et al., “Analytical partitioning of poly(ethylene glycol)-modified proteins”Journal of Chromatography B692(2):263-272 (May 9, 1997).
Delgado et al., “Distinct Influence of PEGylation on the Tumour Localisation of Transferrin and a Tumour-Specific Fab Fragment (F9)”Journal of Cellular Biochemistry(Abstr. A4-101, Keystone Symposium held at Hilton Head Island, SC, Jan 7-13 1995) Suppl. 19A:171 (1995).
Delgado et al., “Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification”British Journal of Cancer73(2):175-182 (Jan. 1996).
Delgado et al., “The uses and properties of PEG-linked proteins”Critical Reviews in Therapeutic Drug Carrier Systems9(3-4):249-304 (1992).
Deuel et al., “Amino acid sequence of human platelet factor 4”Proc. Natl. Acad. Sci.74:2256-2258 (197.
Donnelly et al., “Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups”Lancet341(8846):643-647 (Mar. 13, 1993).
Elling and Kula, “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”Biotechnology and Applied Biochemistry13(3):354-362 (Jun. 1991).
Eno-Amooquaye et al., “Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol”British Journal of Cancer73(11):1323-1327 (Jun. 1996).
Folkesson et al., “Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependen mechanisms”Journal of Clinical Investigation96(1):107-116 (Jul. 1995).
Gonzalez et al., “Humanization of Murine 6G425:An Anti-IL8 Monoclonal Antibody Which Blocks Binding of 1L8 to Human Neutrophils”1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamil Combining Sites(Poster) pps. 1-21 (Feb. 1996).
Harding et al., “Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes”Biochimica et Biophysica Acta1327(2):181-192 (Jul. 25, 1997).
Harris et al., “Synthesis and Characterization of Polyethylene Glycol) Derivatives”J. Polym. Sci., Polym. Chem. Ed.22(2):341-352 (1984).
Haselgrubler et al., “Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols”Bioconjugate Chemistry6(3):242-248 (May-Jun. 1995).
Hebert et al., “Endothelial and Leukocyte Forms of IL-8: Conversion by Thrombin and Interactions with Neutrophils”J. Immunol.145 (9):3033-3040 (Nov. 1, 1990).
Hebert et al., “Interleukin-8: A Review”Cancer Investigation11(6):743-750 (1993).
Herbert, C., “Humanized anti IL-8 antibodies: potential therapy for shock and ARDS?” (Summary of seminar presented at the 1997 Keystone Symposia on The Role of Chemokines in Leukocyte Trafficking and Disease held at
Hsei Vanessa
Koumenis Iphigenia
Leong Steven R.
Presta Leonard G.
Shahrokh Zahra
Dreger Ginger R.
Genentech Inc.
Heller Ehrman White & McAuliffe LLP
Helms Larry R.
LandOfFree
Antibody fragment-polymer conjugates and humanized anti-IL-8... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody fragment-polymer conjugates and humanized anti-IL-8..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fragment-polymer conjugates and humanized anti-IL-8... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387166